AEON Biopharma plans biosimilar development of ABP-450 targeting BOTOX; FDA meeting set for Q3 2024

AEON Biopharma, Inc.

ABP-450 will be developed as a biosimilar using BOTOX as reference product under 351(k) pathway.
Biosimilar initial advisory meeting with FDA scheduled for Q3 2024.
Planned Phase 3 cervical dystonia study of ~400 patients to compare ABP-450 to BOTOX.
No specific financial results for Q2 2024 were disclosed in the press release.
Company notes development is subject to securing funding.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.